Corcept Therapeutics Announces NDA Submission to Be Completed the Week of April 11

by Benzinga Staff
March 31, 2011 4:29 PM | 11 seconds read |
Corcept Therapeutics Incorporated CORT today announced that it will submit its New Drug Application for the use of CORLUX in Cushing's Syndrome to the FDA the week of April 11, 2011.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDAHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!